Press

Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry

Feb 10 • 2 min read

Elemental Advisors Inc. is pleased to announce the launch of PSYK ETF (NYSE: PSYK), a thematic ETF that tracks the performance of the Enhanced Consciousness Index (the “Index”), which is principally comprised of companies involved in the research, development, production and/or use of psychedelics to address medical conditions in legal pharmacological applications under the applicable…

Ehave Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV

Feb 9 • 3 min read

Ehave, Inc. (OTC Pink: EHVVF), a leading healthcare services and technology company, reaffirms its commitment to shareholders to launch its KetaDASH brand by completing the purchase of 100% of Rejuv IV. Rejuv IV provides mobile IV therapy in the San Francisco Bay Area, 7 days a week with flexible scheduling. Rejuv IV provides Ketamine treatments, as well…

Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada

Feb 8 • 3 min read

Mydecine Innovations Group Inc. (NEO: MYCO), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program, which allows healthcare providers to request specific drugs for approved patients who have not responded to…

Sierra Sage Herbs Acquired By Creso Pharma

Feb 7 • 5 min read

Sierra Sage Herbs, maker of the best-selling Green Goo, Southern Butter and Good Goo natural products brands, announced today its acquisition by Australia’s Creso Pharma Limited (ASX: CPH, OTC: COPHF, FRA: 1X8). The deal extends Creso’s global footprint to the US market while adding an additional range of natural health products to its existing lines of cannabis and hemp-based pharmaceuticals. Sierra Sage, which counts 90,000…

Tryp Therapeutics Announces $2,000,000 Financing and Changes in Management, Board of Directors

Feb 4 • 4 min read

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, is pleased to announce a non-brokered private placement to its co-Founder and Executive Director, William J. Garner, M.D. The Placement consists of 11,111,111 million units at a price of $0.18 per Unit, to raise gross proceeds of approximately $2.0 million. Each Unit…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435